Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678443 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01678443 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT01678443, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies. Radiolabeled monoclonal antibodies, such as yttrium-90 anti-CD45 monoclonal antibody BC8, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving radiolabeled monoclonal antibody before a stem cell transplant may be an effective treatment for relapsed or refractory lymphoid malignancies.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL indium In 111 anti-CD45 monoclonal antibody BC8
- RADIATION yttrium Y 90 anti-CD45 monoclonal antibody BC8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 1999-09-01 |
| Est. Completion | 2018-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01678443
The ClinicalTrials.gov registry entry for NCT01678443 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT01678443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01678443 about?
NCT01678443 is a clinical study titled "Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies". This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies. Radiolabeled monoclonal antibodies, such as yttrium-90 anti-CD45 monoclonal antibody BC8, can find cancer cells...
What is the current status of trial NCT01678443?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 1999-09-01. Estimated completion is 2018-09-27.
What interventions are being tested in trial NCT01678443?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), indium In 111 anti-CD45 monoclonal antibody BC8 (BIOLOGICAL), yttrium Y 90 anti-CD45 monoclonal antibody BC8 (RADIATION).
Who is sponsoring clinical trial NCT01678443?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.